drugset / Trial / NCT02963038
CAR T Cells for Refractory B Cell Malignancy
Phase 1/2
Unknown
10 enrolled
Hebei Senlang Biotechnology Inc., Ltd.
The Second Hospital of Hebei Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with B cell malignancy including lymphoma or leukemia.
Timeline
- Start
- 2016-06
- Primary completion
- 2017-06
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous CD19-targeting CAR T cells | Cell therapy | — | — |